NervGen Pharma Corp. Cash Flow-to-Debt Ratio
NervGen Pharma Corp. cash flow-to-debt ratio. NervGen Pharma Corp. (NGEN) has a Cash Flow-to-Debt Ratio of -0.08x as of June 2026, meaning its operating cash flow of $-5.81 Million could theoretically repay 0% of its total liabilities ($73.03 Million) in one year. See NervGen Pharma Corp. free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of NervGen Pharma Corp. (2018–2025)
Cash flow-to-debt ratio of NervGen Pharma Corp. from 2018 to 2025. Historical debt coverage capacity for NervGen Pharma Corp. across 8 annual periods. Also explore NGEN net assets growth trend to track the company's year-over-year net asset growth rate.
NervGen Pharma Corp. Cash Flow-to-Debt Ratio by Year (2018–2025)
NervGen Pharma Corp. cash flow-to-debt ratio by year from 2018 to 2025. Year-by-year debt coverage analysis for NervGen Pharma Corp.. For the full cash flow conversion analysis, see cash flow conversion of NervGen Pharma Corp..
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.99x | $-19.50 Million | $19.73 Million | ▲ +0.8% |
| 2024 | -1.00x | $-16.83 Million | $16.90 Million | ▼ -34.4% |
| 2023 | -0.74x | $-11.30 Million | $15.25 Million | ▲ +56.6% |
| 2022 | -1.71x | $-17.63 Million | $10.32 Million | ▲ +77.7% |
| 2021 | -7.67x | $-8.33 Million | $1.09 Million | ▲ +8.2% |
| 2020 | -8.35x | $-6.32 Million | $756.78K | ▲ +4.7% |
| 2019 | -8.76x | $-8.31 Million | $949.14K | ▼ -391.1% |
| 2018 | -1.78x | $-1.04 Million | $581.26K | — |